Clinical trial
Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for…
NCT00410982 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00410982 |
|---|---|
| Title | Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies |
| Official title | Gemcitabine Combined With Busulfan and Melphalan, With Hematopoietic Cell Transplantation, for Patients With Poor-prognosis Advanced Lymphoid Malignancies |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma, Myeloma |
| Intervention type | Drug, Other |
| Interventions | Busulfan, Gemcitabine, Melphalan, Hematopoietic Cell Transplantation, Rituximab for Patients with B-Cell Malignancies, Palifermin |
| Enrollment | 145 |
| Start date | Dec 1, 2006 |
| Primary completion | Sep 1, 2012 |
| Completion | Sep 1, 2012 |
| First posted | Dec 13, 2006 |
| Last update posted | Jun 3, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: